JP2014080448A - Agent for promoting proliferation of bacteroides in intestine - Google Patents

Abstract

PROBLEM TO BE SOLVED: To provide a food or a pharmaceutical product capable of safely promoting proliferation of Bacteroides with few adverse effects.SOLUTION: An agent for promoting proliferation of Bacteriodes in the intestine includes at least one of polysaccharides and sugar absorption inhibitors. The food or the pharmaceutical product includes the agent.

Description

  The present invention relates to an intestinal bacteroides growth promoter containing a polysaccharide or a sugar absorption inhibitor.

Bacteroides has been conventionally considered to be an opportunistic bacterium with little usefulness. Moreover, since it is an anaerobic bacterium, culture | cultivation is difficult and there are many unknown points including a growth mechanism.
Recent studies have revealed that Bacteroides is a bacterium that has attracted attention for its immunopotentiating action and exhibits a stronger immunostimulating function than lactic acid bacteria that have been pointed out for its immunostimulating action. It has been clarified that the production amount of cytokines involved in IgA and biological defense is also increased in vivo. Bacteroides is reported to be small in obesity and increase with weight loss, and it has been pointed out that it affects the whole body.

As a method for growing Bacteroides, there has been a report on a method for ingesting fructooligosaccharide (FOS), and a certain degree of effect can be expected (see Non-Patent Document 1).
However, in order to produce an effect by ingestion of fructooligosaccharide, a large amount of ingestion is necessary, and there is a physical burden to ingest through diet or functional food. Also, the effect is not sufficient. Therefore, switching to other oral substances was considered, but it was not clear what oral substances other than fructooligosaccharides exhibited a Bacteroides growth promoting effect.
Therefore, there has been a demand for an oral substance that exhibits a sufficient effect at an intake amount that does not impose a physical burden.

Nakanishi, Y. et al. , Murashima, K .; Ohara, H .; , Suzuki, T .; Hayashi, H .; , Sakamoto, M .; Fukasawa, T .; Kubota, H .; Hosono, A .; , Kono, T .; Kaminogawa, S .; Benno, Y .; , Increase in terminal restriction fragments of Bacteroidetes-derived 16S rRNA genes after administration of short-chain fructooligosaccharides. Appl. Environ. Microbiol. , 72, 6271-6, 2006

  The problem to be solved by the present invention is to provide a food or medicine that can promote Bacteroides growth that is safe and has few side effects.

The present inventors have examined a large number of oral substances, and as a result, have found for the first time that certain kinds of oral substances have the effect of growing Bacteroidetes bacteria.
Specifically, the present invention has the following configuration.
[1]
An intestinal Bacteroides growth promoter having an action of growing Bacteroides genus bacteria living in the intestine, characterized by containing a plant extract of the genus Salacia.
[2]
The intestinal Bacteroides growth promoter according to [1], wherein the Salacia plant extract exhibits a 50% inhibitory concentration (IC ₅₀ value) activity of 10 μg / ml to 10,000 μg / ml sucrase.
[3]
The plant of the genus Salacia is at least one plant selected from Salacia reticulata, Salacia oblonga, Salacia chinensis [1] or [2] The intestinal bacteroides growth promoter described in 1.
[4]
The intestinal bacteroides growth according to any one of [1] to [3], wherein the Salacia plant extract is extracted with at least one extraction solvent selected from hot water, ethanol and hydrous ethanol Accelerator.
[5]
A method of growing bacteria of Bacteroides genus living in the intestine using a food or pharmaceutical containing a plant extract of the genus Salacia.
[6]
The Bacteroides genus bacteria inhabiting in the intestine according to [5], wherein the Salacia plant extract exhibits a 50% inhibitory concentration (IC ₅₀ value) activity of sucrase of 10 μg / ml to 10000 μg / ml How to grow.
[7]
The plant of the genus Salacia is at least one plant selected from Salacia reticulata, Salacia oblonga, Salacia chinensis [5] or [6] A method for growing Bacteroides genus bacteria that inhabit the intestine as described in 1.
[8]
The plant extract of Salacia is extracted with at least one extraction solvent selected from hot water, ethanol, and hydrous ethanol, and inhabits the intestine according to any one of [5] to [7] How to grow Bacteroides gate bacteria.
Although this invention is invention which concerns on said [1]-[8], below, other matters (for example, following <1>-<7>) are also described.

<1>
An intestinal bacteroides growth promoter comprising at least one of isomaltoligosaccharide, galactooligosaccharide, mannan oligosaccharide, dietary fiber, and sugar absorption inhibitor.
<2>
The intestinal bacteroides growth promoter according to the above <1>, wherein the dietary fiber is at least one selected from indigestible dextrin.
<3>
The intestinal bacteroides growth promoter according to <1> or <2> above, wherein the sugar absorption inhibitor is an α-glucosidase activity inhibitor.
<4>
The sugar absorption-suppressing substance contains at least one or more selected from Salacia plants, mulberry leaves, gymnemas, and extracts thereof, as described in any one of <1> to <3> above Intestinal Bacteroides growth promoter.
<5>
The intestinal bacteroides according to any one of <1> to <4> above, wherein the sugar absorption inhibitor exhibits a 50% inhibitory concentration (IC50 value) activity of sucrase of 10 μg / ml to 10,000 μg / ml. Growth promoter.
<6>
<4> or <5, wherein the plant of the genus Salacia is at least one plant selected from Salacia reticulata , Salacia oblonga , Salacia chinensis > Intestinal Bacteroides growth promoter.
<7>
A food or pharmaceutical comprising the intestinal bacteroides growth promoter according to any one of <1> to <6> above.

  INDUSTRIAL APPLICABILITY According to the present invention, an intestinal Bacteroides growth promoter and a food or pharmaceutical product that are safe even after long-term use and have few side effects are provided. By taking this, allergic symptoms such as hay fever are alleviated, immune function is improved, such as improvement of immune index, and prevention effects such as cancer are expected.

The intestinal bacteroides growth promoter of the present invention contains at least one of isomaltooligosaccharide, galactooligosaccharide, mannan oligosaccharide, dietary fiber and sugar absorption inhibitor.
The intestinal bacteroides growth promoter of the present invention has an action of growing Bacteroidetes bacteria that inhabit the intestines, and therefore, by taking this agent, It is possible to increase the number of bacteria to which it belongs.
As isomalt-oligosaccharide, galactooligosaccharide and mannan-oligosaccharide, the number of constituent monosaccharides is usually 2 to 90, preferably 2 to 40, more preferably 2 to 20, still more preferably 4 to 6. Things.
The dietary fiber may be water-soluble or insoluble, and includes dextrin, glucomannan, agarose, pectin, cellulose, hemicellulose, chitosan, etc., but indigestible dextrin is more preferable.
When the intestinal Bacteroides growth promoter contains isomalt-oligosaccharide, galactooligosaccharide, mannan-oligosaccharide, dietary fiber, the amount used is preferably 1.5 mg to 170 mg per 1 kg / body weight, more preferably It is 1.5 mg to 150 mg, more preferably 3 mg to 130 mg.
The intestinal bacteroides growth promoter is preferably taken before a normal meal, and preferably taken 3 times a day before every meal.

<Sugar absorption inhibitor>
The sugar absorption inhibitor is a substance having an action of suppressing absorption of sugar into the intestine.
The sugar absorption inhibitor is preferably an α-glucosidase activity inhibitor.

  The α-glucosidase activity inhibiting substance is a substance that inhibits sugar metabolism by inhibiting α-glucosidase activity, and the sucrase 50% inhibitory concentration (IC50 value) is preferably 10 μg / ml to 10,000 μg / ml. When the inhibitory activity is in this range, a glucose absorption suppressing action from the digestive tract can be sufficiently obtained, and a feeling of fullness of the abdomen and generation of gas can be suppressed. The 50% sucrase inhibitory concentration of the α-glucosidase activity inhibitor is more preferably 10 μg / ml to 5000 μg / ml, and even more preferably 10 μg / ml to 2000 μg / ml.

The sucrase 50% inhibitory concentration (IC ₅₀ value) is measured by the following method.

[Experimental method 1] Measurement of sucrase IC ₅₀ value Preparation of sample solution: Weigh 2 mg of sample (α-glucosidase activity inhibitor) into a tube, add 2 mL of water and suspend well, and prepare a sample solution of 1 mg / mL concentration. create. This is diluted with water to 0, 50, 100, 250, and 500 μg / mL, respectively.
Preparation of substrate solution: Sucrose is dissolved in 0.2 M maleate buffer (pH 6.0) to a sucrose concentration of 100 mM, and this is used as a substrate solution.
Preparation of crude enzyme solution: 1 g of an intestinal acetone powder rat (manufactured by SIGMA) was suspended in 10 mL of physiological saline, followed by centrifugation (3,000 rpm, 4 ° C., 5 min). The obtained supernatant is separated to obtain a crude enzyme solution.
400 μL of the substrate solution was added to 500 μL of the sample solution having each concentration described above, and pre-warmed at 37 ° C. for 5 minutes in a water bath. 100 μL of the crude enzyme solution was added to each, and reacted at 37 ° C. for 60 minutes. After completion of the reaction, the enzyme was inactivated by heating at 95 ° C. for 2 minutes to stop the reaction. The produced glucose concentration is quantified using a commercially available kit, mutarotase / glucose oxidase method (glucose CII test Wako, Wako Pure Chemical Industries, Ltd.).
Blank preparation: 200 μL of substrate solution and 50 μL of crude enzyme solution are added to 250 μL of the sample solution of each concentration described above, and the enzyme is heat-inactivated by immediately heating at 95 ° C. for 2 minutes to obtain blank data. .
A calibration curve is prepared from the obtained values, and the concentration at which the enzyme activity is inhibited by 50% (IC ₅₀ value) is determined.

When setting the daily intake or the reference intake of the α-glucosidase activity inhibitor contained in the intestinal bacteroides growth promoter, the α-glucosidase activity inhibitor in the daily intake of the intestinal bacteroides growth promoter For example, when an α-glucosidase activity inhibitor having an IC ₅₀ value of 50 μg / ml is used, 10 to 600 mg is preferable, 40 to 450 mg is more preferable, and 50 to 350 mg is particularly preferable.

  The amount of the α-glucosidase activity inhibitor contained in the intestinal bacteroides growth promoter can be calculated as appropriate from the preferred amount per day. For example, when a tablet with a daily intake of 3 tablets is prepared, it is preferable to contain 1/3 of the daily dose per tablet. That is, the α-glucosidase activity inhibitor is preferably contained in an amount of 3 to 200 mg, more preferably 13 to 150 mg, and particularly preferably 17 to 117 mg.

Moreover, it is preferable that the value calculated | required by following formula 1 is 0.5 or more, It is more preferable that it is 0.8 or more, It is especially preferable that it is 1.7 or more.
The IC ₅₀ value of the intestinal bacteroides growth promoter as a whole is preferably from 0.1 to 7.5, more preferably from 0.15 to 4.50, and more preferably from 0.3 to 3.75 as the value determined by Formula 2. Is particularly preferred.

[Formula 1]
Intestinal Bacteroides growth promoter α-glucosidase activity inhibitor mg in daily intake) / IC ₅₀ value (μg / ml)
[Formula 2]
Intestinal Bacteroides growth promoter (mg) / IC ₅₀ value (μg / ml)

  Saccharide absorption substances include Salacia plants, mulberry leaves, 、 中葉, guava, luffa, bean drum extract, tea leaves, magnolia, 茵 chen 蒿, chenseed, wushu, thin load, bellflowers, 枸 子 子, gomiko, etc. The extract is preferably Salacia plant, mulberry leaf, gymnema, and more preferably these extracts. More preferably, the component contained in the extract of the plant of the genus Salacia, the extract of mulberry leaves, or Gymnema is mentioned.

<Crushed or extract of Salacia plants>
More preferably, the sugar absorption inhibitor is a Salacia plant. A plant of the genus Salacia is usually contained as a pulverized product or an extract.
The plant belonging to the genus Salacia is a plant belonging to the family Nymphalidae that grows mainly in Sri Lanka, India and Southeast Asia, and more specifically, Salacia reticulata , Salacia oblonga , Salacia Prinoides , Salacia chinensis (Salacia chinensis), Salacia latifolia (Salacia latifolia), Salacia Burunoniana (Salacia burunoniana), Salacia grandiflora (Salacia grandiflora), 1 or more selected from the Salacia macro Cum (Salacia macrosperma) Plant is used, Sara A reticulata (Salacia reticulata), Salacia oblonga (Salacia oblonga), is preferably at least one plant selected from the Salacia chinensis (Salacia chinensis).
The pulverized product or extract of a plant belonging to the genus Salacia means a pulverized product, dried product, extract or dried powder (extract powder) of edible parts such as roots, trunks, leaves, flowers, and fruits. One or more kinds of sites may be mixed and used. More preferably, extract powder extracted from roots and trunks is used.

The extract powder is obtained by drying the edible portion or the like obtained by solvent extraction. The extraction solvent may be selected from water, alcohols such as methanol and ethanol, or a mixed solvent of water and alcohols or ketones such as acetone. Preferably, water, alcohol or hydrous alcohol is used. More preferably, hot water, ethanol or hydrous ethanol is used as the extraction solvent. The alcohol concentration of the hydrous alcohol may be 30 to 90% by mass, preferably 40 to 70% by mass.
Examples of the drying method include spray drying and freeze drying, but are not limited thereto.

<Other ingredients>
The intestinal bacteroides growth promoter of the present invention may further contain other components, for example, lactic acid bacteria, mineral yeast, flavonoids, polyphenols, and the like, or oral substances having an immunostimulatory action. .
When the intestinal bacteroides growth promoter contains these components, when the intestinal bacteroides growth promoter is solid, the content is 0.1% by mass to 30% by mass with respect to the entire intestinal bacteroides growth promoter. It is preferable that it is 5 mass%-20 mass%. When the intestinal bacteroides growth promoter is liquid, it is preferably 0.001% by mass to 10% by mass and more preferably 0.01% by mass to 5% by mass with respect to the entire intestinal bacteroides growth promoter. preferable.

  Lactic acid bacteria and bifidobacteria are preferably bacteria that can be administered orally to mammals including humans and that exhibit useful effects in the living digestive tract.

More specifically, those that are harmless to the host, are relatively resistant to gastric acid and bile acids, have a fixability in the living intestine, produce lactic acid, and act to regulate the intestinal microflora. desirable. Such useful lactic acid bacteria, for example acidophilus Lactobacillus (Lactobacillusacidophilus), bifidobacterium (Bifidobacterium longum, etc.), faecalis (Streptococcusfaecalis) reuteri Lactobacillus (Lactobacillus reuteri), caustic lactobacilli (Lactobacilluscasei), Lactobacillus plantarum (Lactobacillus plantarum ), Fell lactofermentum lactobacilli (Lactobacillusfermentum) rhamnosus Lactobacillus (Lactobacillus rhamnosus), Agirusu lactobacilli (Lactobacillusagilis) gasseri bacteria (Lactobacillus Asseri), Mesenterikasu bacteria (Bacillusmesentericus), can be exemplified butyric acid bacteria (Clostridium butyricum) or their subsp like, preferably Lactobacillus acidophilus (Lactobacillusacidophilus), bifidobacterium (Bifidobacterium longum, etc.), faecalis (Streptococcusfaecalis) These lactic acid bacteria can be used singly or in appropriate combination of two or more.

  As long as these lactic acid bacteria are live bacteria, the origin of acquisition is not particularly limited, and those commercially available can be used widely.

  When setting the daily intake or the reference intake of the intestinal bacteroides growth promoter used in the present invention, the number of live lactic acid bacteria in the daily amount of the intestinal bacteroides growth promoter is 10 million to 1000 Billion is preferable, 50 million to 50 billion is more preferable, and 1 to 100 is particularly preferable.

Mineral yeast means yeast containing mineral. As minerals, sodium (Na), potassium (K), chlor (Cl), calcium (Ca), magnesium (Mg), phosphorus (P), sulfur (S), and iron (Fe), zinc called trace elements There are 16 metal elements such as (Zn), copper (Cu), manganese (Mn), cobalt (Co), chromium (Cr), iodine (I), molybdenum (Mo), and selenium (Se). As the mineral yeast used in the present invention, chromium yeast containing chromium is preferable. Although there is no restriction | limiting in particular in the kind of yeast, Baker's yeast or beer yeast is preferable.
The chromium content of the chrome yeast is preferably 0.01 to 5 parts by mass, more preferably 0.05 to 1 part by mass, and particularly preferably 0.1 to 0.3 part by mass with respect to 100 parts by mass of the chrome yeast.
The chromium yeast content in the intestinal bacteroides growth promoter is preferably 3 to 5 parts by mass, more preferably 1 to 10 parts by mass, and more preferably 0.5 to 50 parts by mass with respect to parts by mass of the intestinal bacteroides growth promoter. Particularly preferred.
When setting the daily intake or the reference intake, the amount of chromium yeast in the daily dose of intestinal bacteroides growth promoter is preferably 5 to 500 mg, more preferably 10 to 100 mg, and particularly preferably 30 to 50 mg. The amount of chromium in the daily dose of intestinal Bacteroides growth promoter is preferably 20 to 200 μg, more preferably 40 to 150 μg, and particularly preferably 60 to 100 μg.

Flavonoids are a general term for pigment components present in all organs of plants, and are mainly contained in fruits and vegetables, and are particularly present in the form of glycosides in the leaves of green leaves, white vegetables and citrus fruits.
In the present invention, the flavonoid is a general term for pigment components widely contained in plants, and particularly means a flavan derivative contained in a large amount in vegetables and fruits.

Flavonoids are preferably flavonols, isoflavones and catechins. Flavonols are known as polyphenols.
Flavonoids are substances ingested by the body, but are generally difficult to absorb. However, since flavonoids are effective even in a small amount and are strong antioxidants, it is known that they inhibit the activity of carcinogens, have blood circulation promoting action and antithrombotic action.

In the present invention, flavonoids can be obtained from various sources such as tea, grapes and onions. Here, the term “derived” means a substance extracted from at least a part of the living body. For the extraction, for example, a method for preparing an extract of the above-mentioned Salacia genus plant is applied, and the form of the extract can be the same as described above. For example, the filtrate after extraction or the concentrated or diluted form can be used. Or in the form of its dry powder, or any mixture thereof.
A tea extract containing catechins is prepared from a tea tree, which is an evergreen tree of the camelliaceae family. The tea tree used is either Assamika cultivated in India, Sri Lanka or Southeast Asia, or Camellia sinensis cultivated in China or Japan. In the extraction, usually, water, alcohol or hydrous alcohol is preferably used. More preferably, hot water, ethanol or hydrous ethanol is used as the extraction solvent. The alcohol concentration of the hydrous alcohol may be 30 to 90% by mass, preferably 40 to 70% by mass. Examples of the drying method include spray drying and freeze drying, but are not limited thereto.

The tea extract contains antioxidants such as polyphenols and catechins. Catechin, epicatechin, gallocatechin, epigallocatechin, catechin gallate, epicatechin gallate, gallocatechin gallate or epigallocatechin gallate is preferably included, and epigallocatechin gallate is particularly preferable.
The intestinal Bacteroides growth promoter of the present invention preferably contains 0.1 to 40% by mass of the tea extract, more preferably 0.5 to 35% by mass, and 1.0 to 30% by mass. % Content is particularly preferable.

Further, flavonols, which are one of flavonoids, remove active oxygen and exhibit an antioxidant action such as suppression of arteriosclerosis and improvement of blood flow. Among the flavonols, resveratrol, one of polyphenols, has attracted attention as an antioxidant. Resveratrol is composed of a stilbene skeleton, and is contained in grape skins, and is therefore also contained in red wine made from grapes.
The present invention preferably contains a grape extract or a wine concentrate containing the flavonols as a component.
The intestinal Bacteroides growth promoter of the present invention preferably contains 0.1 to 30% by mass of grape extract, and more preferably 0.1 to 10% by mass.

  Resveratrol has the function of burning fat, preventing arteriosclerosis, which is a disease of the vascular system, preventing cancer, shortening due to DNA cell division, and prolonging cell life similar to that of calorie restriction. It is effective and is known to have excellent effects as a lifestyle-related disease prevention material.

  The content of resveratrol in the intestinal Bacteroides growth promoter of the present invention is preferably 0.0001 to 5.00% by mass, and more preferably 0.001 to 2.00% by mass.

  Among flavonols, quercetin, which is a polyphenol, has attracted attention as an antioxidant. Quercetin has a flavan structure and is abundant in the onion skin.

  Quercetin has been reported to have physiological effects such as vitamin C absorption support, antioxidant action, immune action, etc., and it has been shown to be effective in suppressing fat absorption, and has excellent effects as a lifestyle-related disease prevention material. I know I have

  The content of quercetin in the intestinal bacteroides growth promoter is preferably 0.001 to 15% by mass, more preferably 0.05 to 10% by mass, and further preferably 0.1 to 5.0% by mass. .

In particular, the intestinal Bacteroides growth promoter of the present invention preferably contains 1 to 50% by mass of catechin. As catechins, those derived from green tea are particularly preferred.
Moreover, it is preferable that the intestinal bacteroides growth promoter of this invention contains 2-80 mass% of polyphenols which have a lipase activity inhibitory effect. As polyphenols having a lipase activity inhibitory effect, those derived from oolong tea, grapes, apples, lychees, pine bark, kanka and the like are particularly preferred.

  An oral substance having an immunostimulatory action refers to substances that are said to enhance immune function such as rose flower extract and lotus root derived substances, and the derived substances mean substances extracted from at least a part of the living body. For the extraction, for example, a method for preparing an extract of the above-mentioned Salacia genus plant is applied, and the form of the extract can be the same as described above. Or in the form of its dry powder, or any mixture thereof.

<Usage and formulation>
The intestinal bacteroides growth promoter of the present invention is intended for mammals including humans and is orally administered to the mammals. Here, the term “intestine” refers to the digestive organs where Bacteroides resides and digests and absorbs like human small intestine and human large intestine.
The intestinal Bacteroides growth promoter of the present invention may be food (including beverages), food materials, quasi drugs, pharmaceuticals, pharmaceutical materials, and quasi drugs. Other components include various carriers that are pharmaceutically or food hygienically acceptable for oral administration, such as excipients, lubricants, stabilizers, dispersants, binders, diluents, flavoring agents, sweeteners, A flavoring agent, a coloring agent, etc. can be illustrated.

  The form of the intestinal bacteroides growth promoter of the present invention is not particularly limited as long as it exhibits the effects of the present invention. For example, tablets, pills, granules, fine granules, chewing agents, capsules (hard capsules, Soft capsules), liquids, chewables, beverages and the like. Other food forms may be used.

  These dosage forms can be prepared using conventional methods commonly known in the art.

  In the case of tablets, pills and granules, a dosage form with a conventional coating can be used as necessary, for example, sugar-coated tablets, gelatin encapsulating agents, enteric encapsulating agents, film coating agents and the like. The tablet may be a multilayer tablet such as a double tablet.

  In addition to the above, the intestinal Bacteroides growth promoter of the present invention includes vitamins, vitamin-like substances, proteins, amino acids, fats and oils, organic acids, carbohydrates, plant-derived materials, animal-derived materials, microorganisms, food additives, and pharmaceutical products. Components that can be taken orally, such as additives, can be appropriately contained.

Ingestion of the intestinal bacteroides growth-promoting agent of the present invention increases intestinal bacteroides in the intestinal tract, and intestinal bacteroides are taken up in the Peyer's patch, thereby improving immune function and alleviating allergic symptoms such as pollinosis and atopy. It is also expected to prevent colds and carcinogenesis.
The intestinal bacteroides growth promoter of the present invention is safe even when taken for a long time and has few side effects.

Hereinafter, the present invention will be described using examples, but the present invention is not limited to the following examples.
Hereinafter, Examples 3 to 8 shall be read as Reference Examples 3 to 8, respectively.

Roots and part of the trunk of Salacia Rechikyurata (S. reticulata) and Salacia oblonga (S. oblonga) were mixed in a weight or the like after grinding, spray drying the resulting solution subjected to a hot water extraction step of 98 ° C., Salacia extract powder 1 was obtained. The sucrase IC50 value of Salacia extract powder 1 was 41.
In addition, isomalto-oligosaccharides were obtained from Panorap of Hayashibara Shoji, galacto-oligosaccharides were used from Nissin sugar cup oligos, chitosan, gymnema, and mulberry leaf extracts obtained from Cross Co., Ltd.
Each of these components was dissolved in water for injection and administered as a 10 mg / ml aqueous solution.

(Experimental example 1)
Seven 8-week-old male SD rats were divided, and the following intestinal bacteroides growth-promoting agent was dissolved in water for injection, and an amount of 20 mg / kg / day was ingested for one week using a gastric sonde. In addition, the proportion of bacteria belonging to Bacteroides in the intestinal flora after ingestion was measured by T-RFLP (Nagashima method). However, the amount of the intestinal bacteroides growth promoter in Example 1 was halved (10 mg / kg / day).

  Table 1 shows the ratio of Bacteroides occupying the intestinal flora (rate with the total number of cells as 100%).

As a result of the experimental examples, it was found that the polysaccharide and the sugar absorption inhibitor significantly increased the Bacteroides ratio compared to other foods.
According to the said nonpatent literature 1, although the bacteroides growth effect is acquired by fructooligosaccharide, the amount is administering about 90 times the amount compared with this invention. On the other hand, the present invention has the same effect even in a small amount, and can be ingested easily.
During the study period, there was no difference in body weight between the groups, and no abnormalities such as liver function or kidney function were observed.

Claims (8)

  An intestinal Bacteroides growth promoter having an action of growing Bacteroides genus bacteria living in the intestine, characterized by containing a plant extract of the genus Salacia. The intestinal Bacteroides growth promoter according to claim 1, wherein the Salacia plant extract exhibits 50% inhibitory concentration (IC ₅₀ value) activity of 10 μg / ml to 10,000 μg / ml sucrase.   The plant of the genus Salacia is at least one plant selected from Salacia reticulata, Salacia oblonga, and Salacia chinensis, according to claim 1 or 2. Intestinal Bacteroides growth promoter.   The intestinal Bacteroides growth promoter according to any one of claims 1 to 3, wherein the Salacia plant extract is extracted with at least one extraction solvent selected from hot water, ethanol, and hydrous ethanol. .   A method of growing bacteria of Bacteroides genus living in the intestine using a food or pharmaceutical containing a plant extract of the genus Salacia. The Bacteroides genus inhabiting the intestine according to claim 5, wherein the Salacia plant extract exhibits a 50% inhibitory concentration (IC ₅₀ value) activity of 10 μg / ml to 10,000 μg / ml sucrase. How to grow.   7. The plant of the genus Salacia is at least one plant selected from Salacia reticulata, Salacia oblonga, and Salacia chinensis. To grow bacteria of Bacteroides spp.   The Bacteroides that live in the intestine according to any one of claims 5 to 7, wherein the plant extract of Salacia is extracted with at least one extraction solvent selected from hot water, ethanol, and hydrous ethanol. A method of growing the bacteria of the gate.